Brief: NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label
07/06/2024 14:13
June 7 (Reuters) - Neuraxis Inc NRXS.A :
* NEURAXIS ANNOUNCES NEW SUBMISSION TO THE FDA FOR THE
EXPANSION
OF ITS IB-STIM LABEL; PROVIDES COMPLIANCE WITH NYSE GUIDELINES
ON AUDIT DISCLOSURE
* NEURAXIS INC: NEW SUBMISSION TO FDA TO EXPAND LABEL FOR
IB-STIM
WHICH WOULD INCLUDE AGES 8-21, AND 4 DEVICES OVER 4 WEEKS
Source text for Eikon: ID:nGNX2GqGJ9
Further company coverage: NRXS.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuraxis
See all newsBrief: Neuraxis Inc Expects Net Sales Of About $1.6 Million For Three Months Ended March 31, 2026
Brief: Neuraxis Reports Strong Fourth Quarter And Full Year 2025 Financial Results
Brief: Neuraxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access To More Patients With Functional Abdominal Pain
Brief: Neuraxis Wins First FDA Nod for FD Pain Treatment
Brief: Neuraxis Terminates License Agreement With Masimo